See the DrugPatentWatch profile for Kalydeco
What is Kalydeco, and what approvals has it received?
Kalydeco (ivacaftor) is a cystic fibrosis medicine. Approval decisions depend on which CF mutation a patient has, because Kalydeco is designed for specific genetic classes of the disease. For people with eligible mutations, regulators have approved it as a treatment to improve lung function and related outcomes in cystic fibrosis.
Which CF mutations does Kalydeco cover under approval?
Kalydeco’s approvals are tied to “gating” (class III) CFTR mutations and certain related mutation categories. Patients typically need genetic testing to determine whether their mutation matches the label indications.
When did Kalydeco get approved?
Kalydeco’s original regulatory approvals came after clinical studies showed benefit in the targeted mutation population. The exact year and whether the indication expanded later can vary by regulator and by the specific mutation covered.
How do later approvals or label expansions usually work for Kalydeco?
As more clinical data become available, manufacturers can seek expanded approvals for additional mutations, broader age ranges, or new dosing schedules. Each expansion still depends on demonstrating benefit for the specific patient group covered by the label.
What should patients check when asking about “Kalydeco approval”?
The key practical step is to confirm that the patient’s specific CFTR mutation matches the approved indication in the country’s prescribing information. If the mutation is not included in the label, approval for coverage and access may differ even if studies exist for other mutations.
Where can I verify the latest “Kalydeco approval” and label/coverage details?
For regulatory status, brand-to-generic context, and patent/exclusivity research that can affect access, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/